First drug OK'd to treat dementia of Parkinson's disease
Until now, Novartis Corp.'s Exelon (rivastigmine tartrate) was approved to treat mild to moderate dementia associated with Alzheimer's disease. Now the drug has gained a new indication-to treat mild to moderate dementia related to Parkinson's disease.
First drug OK'd to treat dementia of Parkinson's disease
Until now, Novartis Corp.'s Exelon (rivastigmine tartrate) was approved to treat mild to moderate dementia associated with Alzheimer's disease. Now the drug has gained a new indication-to treat mild to moderate dementia related to Parkinson's disease. FDA noted that this approval fills a void, since to date there has been no treatment targeted at Parkinson's-related dementia.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
